Clin2
NCT07861152Possibly a fitNot yet recruiting

New treatment for Graves' disease

Graves' Disease

Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.

This trial tests a new medicine called REGN24493 that may help control Graves' disease by blocking a specific receptor in the body. It is designed for adults who have been diagnosed with Graves' disease and are currently stable on their thyroid levels.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
45 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have been diagnosed with Graves' disease for at least 4 months.
  • You must have a positive test for thyroid-stimulating hormone receptor antibodies (TRAb) at the screening visit.
  • Your thyroid hormone levels must be normal (euthyroid) at screening and for at least 4 weeks before.
  • Your body mass index (BMI) must be between 18.5 and 35.0.
  • You cannot have had radioactive iodine treatment or thyroid surgery in the past.
  • You cannot be currently taking levothyroxine (a thyroid hormone replacement) within the last 6 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07596849Recruiting· Phase 3
Testing a New Injection for Graves' Disease

This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.

Pazardzhik
NCT07661056Recruiting· Phase 3
Investigational drug for treating graves' disease overactive thyroid

This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.

Tucson, Arizona
NCT06727604Recruiting· Phase 2
Study of IMVT-1402 for Graves' disease not controlled by medication

This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.

Phoenix, Arizona
NCT07018323Recruiting· Phase 2
Study of IMVT-1402 for Graves' disease

This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.

Tucson, Arizona
NCT07305818Recruiting· Phase 1
Testing a new drug for Graves' disease

This study tests a new medication called MER511 for adults with Graves' disease. The goal is to see if it is safe and how it works when taken once or multiple times.

Torrance, California
NCT05461820Recruiting· Phase 4
Testing treatment options for Graves’ disease and its relapse

This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.

Nanjing

Hear when a new Graves Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.